Clinical trials: Cancer, Gastrointestinal
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Anal Cancer
A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
Prospective, open-label, within-subject, multi-center pilot study of Lymphoseek in the detection of lymph nodes in subjects with known squamous cell carcinoma of the anus.
- Trial name
- NCT02857608
- Testing
- Lymphoseek
- Sponsor
- Cardinal Health 414, LLC
Colorectal Cancer (CRC)
Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of…
- Trial name
- CLIMBED (NCT07168876)
- Where
- Argentina
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Epiliquid Holding, Inc
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT05257590
- Testing
- Nivolumab Injection [Opdivo], CVM-1118
- Where
- 5 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- TaiRx, Inc.
Hepatocellular Carcinoma
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC)…
- Trial name
- PROACTIF (NCT04069468)
- Testing
- TheraSphere
- Where
- 37 sites in France
- Volunteers
- 1,247 people
- Sponsor
- Boston Scientific Corporation
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Tumors Cancer, PDAC
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
This is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To…
- Conditions
- Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
- Trial name
- NCT07259590
- Testing
- GFH375
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Pancreatic Cancer
DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have metastatic…
- Trial name
- NCT00003951
- Testing
- exatecan mesylate
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Colorectal Cancer
Informed Choice - Compass
The primary objective of this study is to evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices on CRC screening rates and time adherent to CRC guidelines.
- Trial name
- NCT05246839
- Testing
- Brief Video, Brief Video Plus
- Where
- 39 sites in United States
- Volunteers
- 1,823 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Gastric (Stomach) Cancer, GastroEsophageal Cancer
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC.
- Conditions
- Gastric (Stomach) Cancer, GastroEsophageal Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
- Trial name
- NCT07481357
- Testing
- DA-3501
- Where
- 3 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Dong-A ST Co., Ltd.
Hepatocellular Carcinoma
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo…
- Trial name
- NCT05359861
- Testing
- Casdozokitug, Atezolizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Coherus Oncology, Inc.
Hepatocellular Carcinoma
Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced primary hepatocellular carcinoma The primary endpoint is best overall response rate within 20 weeks after registration
- Trial name
- NCT00405873
- Testing
- AMT2003
- Where
- 2 sites in Germany
- Volunteers
- 73 people
- Sponsor
- Auron Healthcare GmbH
Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and…
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Trial name
- GOBLET (NCT07280377)
- Testing
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
- Where
- 15 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Oncolytics Biotech
Advanced Unresectable Pancreatic Cancer
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer
To investigate the efficacy of GV1001 in sequential combination with gemcitabine in locally advanced and metastatic adenocarcinoma of the pancreas.
- Trial name
- NCT00358566
- Testing
- GV1001, Gemcitabine (Chemotherapy)
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Pharmexa A/S
Liver Cancer
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
- Trial name
- NCT00191412
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.